The CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Studies) trial randomized more than 10,000 patients with previous myocardial infarction (MI) and high-sensitivity C-reactive protein levels of 2 mg/L or higher to receive the IL-1β inhibitor canakinumab (50, 150, or 300 mg every 3 months) or placebo. This evidence concerns the gene CRP and myocardial infarction.